Antidpressant, Fluvoxamine, Reduces Severe Covid-19 Disease, Study FindsBy Radiant Health
Published: October 31, 2021
A new study published in Lancet Global Health found that a 10-day course of fluvoxamine (brand name Luvox), a drug commonly prescribed for depression and obsessive-compulsive disorder, significantly reduced the need for hospitalization by 66% and cut deaths by 91% in people at high risk of severe covid-19 disease. A full treatment course with fluvoxamine costs about $10 compared to $700 for a 5-day treatment course with Merck’s antiviral pill, molnupiravir. The expert panel that develops US Covid-19 treatment guidelines has been briefed on the study data and could decide soon about recommending fluvoxamine as an early treatment.
Like what you're reading? Sign up for our free newsletter and never miss a post! Plus get a FREE digital version of our Issue No.10 with sign up.
- Some Americans Will Have Medical Debt Wiped From Credit - July 9, 2022
- Natural Gas Used to Heat Homes Contains Some Harmful Chemicals - July 9, 2022
- Uterine Cancer Claims Many Black Lives - July 9, 2022
- Babies and Toddlers Get COVID-19 Shots - June 27, 2022
- FDA Bans Juul’s E-Cigarettes and Cartridges - June 27, 2022
- Polio Virus Found in London Sewage - June 27, 2022
- 200 Million Americans Are Drinking Contaminated Water - June 19, 2022
- Young Kids Can Finally Get Vaccinated Against COVID-19 - June 19, 2022
- New Regulations for Baby Sleep Products - June 19, 2022
- FDA Approves First Drug for Alopecia Hair Loss - June 19, 2022